Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul M J Clement

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Sarcoma|May 15, 2007
Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patientsG Huygh, Paul M J Clement, H Dumez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2008
Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group StudyEric Raymond, Alba A Brandes, Christian Dittrich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2010
Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastomaRoger Stupp, Monika E Hegi, Bart Neyns, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2022
Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II StudyAndrew B Lassman, Juan Manuel Sepúlveda-Sánchez, Timothy F Cloughesy, et al.
European Journal of Cancer (Oxford, England : 1990)|February 18, 2021
Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastomaPaul M J Clement, Linda Dirven, Marica Eoli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2025
INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab Plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaJérôme Fayette, Lisa Licitra, Kevin Harrington, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Sarcoma|May 15, 2007
Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patientsG Huygh, Paul M J Clement, H Dumez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2008
Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group StudyEric Raymond, Alba A Brandes, Christian Dittrich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2010
Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastomaRoger Stupp, Monika E Hegi, Bart Neyns, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2022
Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II StudyAndrew B Lassman, Juan Manuel Sepúlveda-Sánchez, Timothy F Cloughesy, et al.
European Journal of Cancer (Oxford, England : 1990)|February 18, 2021
Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastomaPaul M J Clement, Linda Dirven, Marica Eoli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2025
INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab Plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaJérôme Fayette, Lisa Licitra, Kevin Harrington, et al.
Pageof 2